Freiburg, May 7th, 2025
Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat [...] Read more »
Dr. Falk Pharma gibt positive Ergebnisse seiner zulassungs-relevanten Phase-III-Studie zu Norucholsäure bei primär sklerosierender Cholangitis bekannt
Freiburg, den 7. Mai 2025
Die Studienergebnisse zeigen die Überlegenheit von Norucholsäure (NCA) gegenüber Placebo im kombinierten primären Endpunkt. Es gibt derzeit kein zugelassenes [...] Read more »
Sabin Begins Marburg Vaccine Trial in U.S.
WASHINGTON, April 16, 2025 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute has launched a multi–site Phase 2 clinical trial in the U.S. for its Marburg vaccine candidate, administering doses to the [...] Read more »
Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson Syndrome
MNV–201 is Minovia’s second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria
Read more »
Society for Clinical Research Sites (SCRS) e Fortrea Fazem Parceria para Promover a Colaboração na Pesquisa Clínica
DURHAM, N.C., Feb. 20, 2025 (GLOBE NEWSWIRE) — A Society for Clinical Research Sites (SCRS) e a Fortrea (Nasdaq: FTRE), uma organização líder global de pesquisa por contrato (CRO), tem o prazer de anunciar o [...] Read more »
La Society for Clinical Research Sites (SCRS) et Fortrea s’associent pour promouvoir la collaboration dans le domaine de la recherche clinique
DURHAM, N.C., 20 févr. 2025 (GLOBE NEWSWIRE) — La Society for Clinical Research Sites (SCRS) et Fortrea (Nasdaq : FTRE), l’une des principales organisations de recherche contractuelle (ORC) à [...] Read more »
Society for Clinical Research Sites (SCRS) und Fortrea gehen eine Partnerschaft zur Förderung der Zusammenarbeit in der klinischen Forschung ein
DURHAM, North Carolina, Feb. 20, 2025 (GLOBE NEWSWIRE) — Die Society for Clinical Research Sites (SCRS) und Fortrea (Nasdaq: FTRE), ein führendes globales Auftragsforschungsinstitut (Contract Research Organization, [...] Read more »
Society for Clinical Research Sites (SCRS) and Fortrea Partner to Advance Collaboration in Clinical Research
DURHAM, N.C., Feb. 20, 2025 (GLOBE NEWSWIRE) — The Society for Clinical Research Sites (SCRS) and Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), are pleased to announce Fortrea’s [...] Read more »
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases
– Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD–19 x FcγRIIb inhibitor of B cell function–
–Topline results from Phase 2 Trial in [...] Read more »
Sabin Vaccine Institute Delivers Marburg Vaccines to Combat Outbreak in Rwanda
[Caption] Sabin Vaccine Institute delivered 700 doses of its Marburg vaccine to Rwanda on Oct. 5, 2024.
WASHINGTON, Oct. 05, 2024 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute has provided [...] Read more »